Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 17/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ponalrestat SCHEMBL29498248 | 1.00 | AKR1B1 (1.00) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| Ponalrestat SCHEMBL49154 | 1.00 | AKR1B1 (1.00) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11175078 | 0.90 | AKR1B1 (0.82) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| Ponalrestat SCHEMBL11166654 | 0.89 | AKR1B1 (0.80) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| Ponalrestat SCHEMBL10702188 | 0.89 | AKR1B1 (0.80) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL9218514 | 0.89 | AKR1B1 (0.80) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11172039 | 0.88 | AKR1B1 (0.79) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11167901 | 0.88 | AKR1B1 (0.78) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL9321689 | 0.88 | AKR1B1 (1.00) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11165597 | 0.87 | AKR1B1 (0.77) | AKR1B1MEN1CYP1A2CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024053761-A1 | COMPOSITION FOR PROMOTING MYOBLAST PROLIFERATION AND DIFFERENTIATION CONTAINING ALDOSE REDUCTASE INHIBITOR | 애니머스큐어 주식회사 | 2024-03-14 | — | — | WO | claimed |
| WO-2024053761-A1 | COMPOSITION FOR PROMOTING MYOBLAST PROLIFERATION AND DIFFERENTIATION CONTAINING ALDOSE REDUCTASE INHIBITOR | 애니머스큐어 주식회사 | 2024-03-14 | — | — | WO | disclosed |
| CN-114656371-B | 1, 4-cyclohexanediamine bridged compounds and their use in the treatment of disorders of glucose metabolism | 广州药本君安医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11622951-B2 | Alpha-aminoadipate for treatment of vision loss and restoring sight | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622951-B2 | Alpha-aminoadipate for treatment of vision loss and restoring sight | AADAT, PDE6A, PDE6C | AKR1B1 132/4885MEN1 1331/4885CYP1A2 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.